| Expression pattern: |
UP |
| Associated gene: |
SLC2A1 |
| Associated microRNA: |
miR-378b |
| Biological function: |
Enhances glioma cell survival, proliferation, migration/invasion and glycolysis; inhibits apoptosis; promotes tumor growth in vivo. |
| Molecular mechanism: |
Acts as a ceRNA by sponging miR-378b to relieve repression of SLC2A1 (GLUT1), enhancing glycolysis and malignant phenotypes in glioma. |
| Biological pathway or process: |
proliferation (promotes); apoptosis (inhibits); migration (promotes); invasion (promotes); glycolysis (promotes); EMT (promotes); ceRNA regulation (promotes) |
| Detected method: |
Q
|
| Validation methods: |
RT-qPCR; Clinical Sample Validation; Bioinformatics Analysis; RIP (RNA Immunoprecipitation); RNA Pull-Down; Luciferase Reporter Assay; Transfection; CCK8; EdU Staining; Annexin V/PI Flow Cytometry; Transwell Assay; Western Blot; In Vivo Animal Model |
| Clinical significance: |
- |
| Description: |
circZNF609 is up-regulated in clinical glioma samples and promotes glioma proliferation, invasion/migration, EMT-like changes, and glycolysis while suppressing apoptosis. Mechanistically it sponges miR-378b to increase SLC2A1 (GLUT1) expression, and its knockdown suppresses xenograft tumor growth. |
| Confidence score: |
0.7294 |